|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||196.25 - 200.27|
|52 Week Range||187.16 - 468.55|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||19.49|
|Earnings Date||Apr 20, 2022 - Apr 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||317.17|
When the pandemic hit, in-person lessons at the Community Lab paused. That’s when Biogen-Lemelson-MIT Program Biotech in Action launched, providing online science and lab classes. Going virtual all...
Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.
Biogen stock popped Tuesday after the company's partner, Eisai, finished submitting its application for an experimental Alzheimer's drug.